23andMe Holding Co logo

23andMe Holding Co

$ 3.08 +0.07 (+2.33%) 04:00 PM EST
P/E:
At Loss
P/B:
1.71
Market Cap:
$ 1.40B
Enterprise V:
$ 1.04B
Volume:
2.04M
Avg Vol (2M):
2.59M
Volume:
2.04M
Market Cap $:
1.40B
PE Ratio:
At Loss
Avg Vol (2-Month):
2.59M
Enterprise Value $:
1.04B
PB Ratio:
1.71

Business Description

Description
23andMe is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. More than 80% of 23andMe customers voluntarily elect to share their de-identified genetic data with the company, which is used to develop future reports. In 2018, GlaxoSmithKline made an equity investment in the company, entering a five-year collaborative agreement with 23andMe to develop drug candidates.
Name Current Vs Industry Vs History
Cash-To-Debt 5.02
Equity-to-Asset 0.79
Debt-to-Equity 0.1
Debt-to-EBITDA -0.28
Interest Coverage N/A
N/A
N/A
Piotroski F-Score N/A/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 1.59
Distress
Grey
Safe
Beneish M-Score 4.45
Manipulator
Not Manipulator

Growth Rank

Name Current Vs Industry Vs History
Future 3-5Y Total Revenue Growth Rate 3.9

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 44.05
9-Day RSI 47.55
14-Day RSI 48.52
6-1 Month Momentum % 22.59
12-1 Month Momentum % -64.22

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 3.49
Quick Ratio 3.4
Cash Ratio 2.84
Days Inventory 32.45
Days Sales Outstanding 26.85
Days Payable 41.74

Dividend & Buy Back

Name Current Vs Industry Vs History